Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2070169 | 0.82 | CYP1A2 (0.55) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL160214 | 0.81 | CYP1A2 (0.53) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL31412793 | 0.81 | CYP1A2 (0.53) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL25234479 | 0.80 | DAGLA (0.42) | CYP1A2MAPTALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL2070116 | 0.80 | CYP1A2 (0.49) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL369268 | 0.79 | CYP1A2 (0.51) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL9714181 | 0.79 | CYP1A2 (0.51) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL1931216 | 0.79 | CYP1A2 (0.51) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL24499444 | 0.79 | CYP1A2 (0.51) | CYP1A2NLRP3MAPTALDH1A1NPC1 | |
| SCHEMBL10265647 | 0.79 | CYP1A2 (0.51) | CYP1A2NLRP3MAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-3725798-B1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-03-04 | — | — | EP | disclosed |
| EP-4696316-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042740-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4054719-B1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12516046-B2 | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| EP-4667495-A2 | BIOACTIVE MOLECULE CONJUGATE, PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-12-24 | — | — | EP | disclosed |
| EP-4665373-A2 | SELECT THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS Oncology, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100016371-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20090298866-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
| EP-2044062-A1 | INDOLE COMPOUNDS | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| EP-2041086-A1 | INDOLE COMPOUNDS | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| WO-2008006790-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006793-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| EP-1874776-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006114274-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | PTGER1, PTGER2, PTGER4 | CYP1A2 61/4885NLRP3 910/4885MAPT 4703/4885 |
| US-20260042740-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 4723/4885NLRP3 4779/4885MAPT 4692/4885 |
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | GABRB2, GABRB1, GABRB3 | CYP1A2 1952/4885NLRP3 4041/4885MAPT 1142/4885 |
| US-20100016371-A1 | Indole Compounds | IDO1, TPH1, IDO2 | CYP1A2 37/4885NLRP3 1123/4885MAPT 2296/4885 |
| US-20090298866-A1 | Indole Compounds | IDO1, TPH1, IDO2 | CYP1A2 36/4885NLRP3 1657/4885MAPT 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.